TNYA
Tenaya Therapeutics IncKey Statistics
About Tenaya Therapeutics Inc
Tenaya Therapeutics Inc. is a forward-thinking clinical-stage biotechnology firm dedicated to revolutionizing the treatment landscape for heart disease via its proprietary engineered heart cell platform. With a strong pipeline that features cutting-edge gene therapies and regenerative solutions, Tenaya is well-positioned to address critical unmet needs within cardiovascular medicine, presenting compelling growth prospects in the biopharmaceutical industry. The company's focus on scientific excellence and commitment to improving patient outcomes positions it as a noteworthy investment opportunity for institutional investors keen on fostering advancements in cardiac care and capitalizing on the dynamic cardiovascular therapy market.
Fundamentals
| Revenue (TTM) | 225,000 |
| Gross Profit (TTM) | 225,000 |
| EBITDA | $-78.32M |
| Operating Margin | -8918.00% |
| Return on Equity | -73.60% |
| Return on Assets | -38.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.57 |
| Price-to-Book | 1.59 |
| Price-to-Sales (TTM) | 745.03 |
| EV/Revenue | 436.04 |
| EV/EBITDA | -0.67 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $217.00M |
| Float | $216.08M |
| % Insiders | 0.47% |
| % Institutions | 48.32% |
Historical Volatility
Volatility is currently contracting